8-K: HilleVax Stockholders Re-Elect Directors and Ratify Auditor at 2025 Annual Meeting

HilleVax, Inc. announced the successful election of three Class III directors and the ratification of Ernst & Young LLP as its independent registered public accounting firm for fiscal year 2025 at its Annual Meeting of Stockholders held on June 23, 2025.

Summary

• HilleVax, Inc. held its 2025 Annual Meeting of Stockholders on June 23, 2025.
• Stockholders re-elected Robert Hershberg, M.D., Ph.D., Jeryl Hilleman, and Aditya Kohli, Ph.D. as Class III directors.
• Each elected director will serve a three-year term expiring at the Company's 2028 Annual Meeting of Stockholders.
• Robert Hershberg received 22,286,355 votes For, 1,574,443 Withheld, and 14,522,437 Broker Non-Votes.
• Jeryl Hilleman received 22,039,977 votes For, 1,820,821 Withheld, and 14,522,437 Broker Non-Votes.
• Aditya Kohli received 22,355,721 votes For, 1,505,077 Withheld, and 14,522,437 Broker Non-Votes.
• Stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal 2025.
• The ratification of Ernst & Young LLP received 38,241,645 votes For, 133,485 votes Against, and 8,105 Abstentions.

Sentiment

Score: 5

Explanation: The document reports routine corporate governance matters with expected outcomes, indicating a neutral sentiment. There are no unexpected positive or negative developments.

Positives

• The successful election of all proposed Class III directors indicates continued stability in the company's board leadership.
• The overwhelming ratification of Ernst & Young LLP as the independent auditor suggests strong shareholder confidence in the company's financial oversight and reporting processes.

Future Outlook

The document primarily reports on past voting results and does not contain specific forward-looking statements or financial guidance.

Management Comments

• Paul S. Bavier, General Counsel and Chief Administrative Officer, signed the report on behalf of HilleVax, Inc.

Industry Context

This 8-K filing is a routine corporate governance update, common across all publicly traded companies, reflecting the standard process of holding annual stockholder meetings to elect directors and ratify auditors. It does not provide specific insights into HilleVax's operational or strategic position within the biotechnology or pharmaceutical industry, but rather confirms adherence to regulatory and governance requirements.

Corporate Governance

Stakeholder Impact

• Shareholders: The election of directors and ratification of the auditor directly impacts shareholder representation and confidence in financial reporting and corporate oversight.
• Management: The re-election of directors provides stability to the board, which oversees management.

Next Steps

• The newly elected Class III directors will serve until the Company's 2028 Annual Meeting of Stockholders.

Key Dates

Keywords

HilleVax, HLVX, Annual Meeting, Stockholders, Board of Directors, Director Election, Auditor Ratification, Ernst & Young LLP, Corporate Governance, SEC Filing, 8-K